Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Measuring somatic mutations in humans?
- The Cancer Genome Atlas
- Increase in exome mutations in tumors with age
- Detecting mutations in normal cells, genome-wide
- Somatic mutation in cancer and normal cells
- Limitations of somatic mutations analysis
- Somatic mutations detection by single-cell WGS
- Spontaneous/induced point mutations in S2 cells
- Single-cell mutation analysis
- Artefactual GC to AT transitions
- Mutation frequency after cell lysis (low/high temp)
- FDR and sensitivity estimation from kindred groups
- Somatic mutations as a biomarker for aging
- Why is the germline immortal?
- CNV and LOH in single blastomeres
- Germline vs. somatic mutation frequencies
- Human vs. mouse germline and somatic mutations
- Human vs. mouse mutations corrected for mitoses
- Conclusions and future prospects
- Genetic (and epigenetic) drift implications
- Acknowledgments
Topics Covered
- Measuring somatic mutations in humans
- How to detect mutations in normal cells, genome-wide, in humans?
- If DNA damage and mutations drive aging, why is the germline immortal?
Talk Citation
Vijg, J. (2017, July 31). DNA damage, mutations and aging 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 10, 2024, from https://doi.org/10.69645/WFVZ7734.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Jan Vijg has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
DNA damage, mutations and aging 2
Published on July 31, 2017
28 min
Other Talks in the Series: Aging
Transcript
Please wait while the transcript is being prepared...
0:04
So the next question for us was, how can we, first of all,
escape the limits of that reporter and really look at the genome overall?
There are so many interesting features in a genome and we really want to see where
the mutations are because maybe the reporter is
not such a great measure for the genome overall,
and there are all sorts of differences maybe between genes and regulatory sequences.
And second, how can we expand our studies, or in general how can we
expand studies of somatic mutations to humans, from experimental animals to humans?
The first thing we tried is basically try to hitchhike on data that were available,
that were collected by others.
And it's a student in the lab,
another student Brandon Milholland,
who started to do this.
0:48
Brandon began to use what we called
the Cancer Genome Atlas after the emergence of next generation sequencing,
so the capacity to really sequence the genome or
a substantial part of the genome at low cost and very quickly and
efficiently. That was used, that technology, for
sequencing tumors because a tumor obviously originates from one cell,
it's essentially a clone.
So you can take that tumor and basically sequence the genome and they have
all the mutations that vary in that original cell when it was still normal,
but also that started to accumulate in the tumor itself once it was already a tumor.
That's all put together in the Cancer Genome Atlas so others have collected the data,
we didn't collect it. But Brandon could access it,
because it is free, you can look at it.
1:33
This, sort of, summarizes his studies which have been published recently.
I think it's really important to some extent it confirms what was already
known or suspected in a number of papers on individual cancers.
We had already noticed that when it was a cancer,
like a juvenile tumor in young patients,
they generally didn't contain that many mutations.
The way you looked at tumors from older people there were many more mutations.
And Brandon sort of confirmed that and studied this in a large number of patients,
so you see about 7000.
And he really showed proofs, I think without a doubt, that you
see mutations in these tumors increasing as a function of age,
and it increases exponentially.
So it's pretty dramatic, actually.
So the argument here is of course that yes,
maybe so now and then a tumor will begin to
accumulate many mutations after it stopped being normal.
That's true, but probably in virtually all cases most of
the mutations in the tumor were actually already there in a normal cell,
and there's also other evidence that that's exactly the case.
So clearly that is another piece of convincing evidence but now in humans that yes,
mutations do accumulate as a function of age in different cell types.
Obviously that's really not what we were ultimately interested in.
We really want to look at normal tissues, normal cells,
and check if mutations accumulate in these normal tissues.